-F Demichelis Researcher Activity Profile

Research Author Detailed Information 

F Demichelis Publication Rate By Year

F Demichelis has published 1 paper(s) in 2006, 11 paper(s) in 2007, 4 paper(s) in 2008, for a total of 16 research publications in total.

F F Demichelis Author Information

LAST NAME: demichelis

FIRST NAME: F

INITIALS: f

AFFILIATION:

Papers

F Demichelis's Publication Record

1. Morphological features of TMPRSS2-ERG gene fusion prostate cancer. Year Published: 2007
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115-6110, USA.
2. Optimization of optical parameters and electric field distribution in multilayers. Year Published: 2008
3. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Year Published: 2006
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, EBRC 442A, 221 Longwood Avenue, Boston, MA 02115-6110, USA.
4. Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. Year Published: 2007
Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115-6110, USA.
5. Automated immunofluorescence analysis defines microvessel area as a prognostic parameter in clear cell renal cell cancer. Year Published: 2007
Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
6. TMPRSS2-ETS fusion prostate cancer: biological and clinical implications. Year Published: 2007
Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
7. Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer. Year Published: 2007
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
8. TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. Year Published: 2007
Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
9. TMPRSS2-ETS fusion prostate cancer: biological and clinical implications. Year Published: 2007
Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
10. Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma. Year Published: 2007
Broad Institute, Massachusetts Institute of Technology and Harvard University, 7 Cambridge Center, Cambridge, MA 02142, USA.
11. TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. Year Published: 2007
Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
12. Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma. Year Published: 2007
Broad Institute, Massachusetts Institute of Technology and Harvard University, 7 Cambridge Center, Cambridge, MA 02142, USA.
13. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Year Published: 2007
Broad Institute, Massachusetts Institute of Technology and Harvard University, 7 Cambridge Center, Cambridge, MA 02142, USA.
14. Nine-gene molecular signature is not associated with prostate cancer death in a watchful waiting cohort. Year Published: 2008
Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 3rd Floor, 181 Longwood Avenue, Boston, MA 02115. lmucci@hsph.harvard.edu.
15. Nine-gene molecular signature is not associated with prostate cancer death in a watchful waiting cohort. Year Published: 2008
Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA. lmucci@hsph.harvard.edu
16. Nine-gene molecular signature is not associated with prostate cancer death in a watchful waiting cohort. Year Published: 2008
Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA. lmucci@hsph.harvard.edu